M
Mediar Therapeutics
Preclinical stage biotech company developing medicines to halt, or even reverse, fibrosis
About Mediar Therapeutics
Mediartx.com, operating under the name Mediar, is a biotech startup that is breaking new ground in the treatment of fibrosis, a disease characterized by the thickening and scarring of connective tissue. The company's unique approach targets fibrotic mediators, which are key drivers of disease progression, offering a new perspective and renewed hope for patients.
Mediar's market is primarily in the healthcare and pharmaceutical industry, specifically in the area of fibrosis treatment. The company serves a broad range of clients, including healthcare providers, patients suffering from fibrosis, and other stakeholders in the healthcare sector.
The business model of Mediar is based on the research, development, and commercialization of innovative fibrosis treatments. The company's team of industry-leading researchers leverages their deep expertise in fibrosis, antibody engineering, and translational science to accelerate clinical proof-of-concept studies. This approach allows Mediar to create and patent unique treatments, which are then sold or licensed to healthcare providers or pharmaceutical companies.
In terms of revenue generation, Mediar makes money through the sale or licensing of its patented treatments. The company also likely seeks funding from investors who are interested in the biotech industry and see the potential in Mediar's innovative approach to fibrosis treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 78.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $76M | $425M | Longwood Fund · Alexandria Equities · Crystal IS · Intermediate Capital Group | ↗ |
| SERIES AOther financing | Mar 2023 | $85M | $340M | Bristol-Myers Squibb · Pfizer Ventures · Pureos Bioventures · Mission BioCapital | ↗ |
Growth signals
Latest recorded traffic for Mediar Therapeutics is 5.2K monthly website visits, up 116.7% over the last three months. Mediar Therapeutics's team grew 8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Mediar Therapeutics in the Cambridge ecosystem
The Mediar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Ono Venture Investment
Agent Capital
Mission BioCapital
Ono Pharmaceutical
Series A13 investors entered at this stage
Sofinnova Partners
Novartis Venture Fund
Bristol-Myers Squibb- PVPfizer Ventures
Pureos Bioventures
Gimv
Eli Lilly
Mass General Brigham Ventures
Intermediate Capital Group
Amplitude Ventures
Longwood Fund
Alexandria Equities- CICrystal IS
Other known investors2 additional known investors
Brigham and Women's Hospital
Massachusetts General Hospital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mediar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mediar Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







